June 19, 2026—Proscia introduced the fifth generation of its Concentriq platform, the most significant advancement to the platform in five years.
The new generation introduces intelligence that draws on clinical and scientific context to support experts throughout drug discovery, development, and case review. The new architecture brings domain-specific frontier vision, language, and multimodal models into the core of the platform while maintaining enterprise-scale security, governance, and reliability. The architecture enables the platform to unify images, metadata, and the context surrounding a case or study—from slide-level morphology and patient history to laboratory-specific protocols and translational data—giving experts and models the same full picture. “Intelligence draws on this picture to orchestrate the burdensome work surrounding case review and accelerate the discovery and development of advanced biomarkers,” according to a press release from Proscia. “Outputs are transparent, reproducible, and interpretable for expert verification.”
The platform is available now to current customers through the company’s early access program, with broader availability later this year.